Treatment of Cirrhosis with Portal Hypertension

Introduction to Treatment Guidelines

The American Association for the Study of Liver Diseases recommends treating the underlying liver disease, implementing non-selective beta-blockers (NSBBs) for patients with clinically significant portal hypertension and varices, and using transjugular intrahepatic portosystemic shunt (TIPS) for refractory complications 1, 2

The European Association for the Study of the Liver suggests focusing exclusively on treating the underlying etiology in stage 1: mild portal hypertension (HVPG 5-10 mmHg) 1, 3
Remove causative factors: alcohol cessation, antiviral therapy for hepatitis B/C, weight loss for NAFLD, immunosuppression for autoimmune hepatitis 4, 5
The American College of Gastroenterology recommends against initiating NSBBs in stage 1: mild portal hypertension (HVPG 5-10 mmHg), as they are ineffective and increase adverse events without benefit 1, 2, 6

The American Association for the Study of Liver Diseases recommends initiating NSBBs immediately in stage 4: compensated cirrhosis with large varices (F2/F3) or high-risk small varices, with carvedilol 12.5 mg/day as first-line therapy 1, 2, 6
Carvedilol is superior to traditional NSBBs (propranolol/nadolol) in achieving hemodynamic response, with a target dose of 12.5 mg/day 2, 5, 6

The International Society for Hepatic Encephalopathy and Nitrogen Metabolism recommends initiating vasoactive drugs immediately when variceal hemorrhage is suspected, before endoscopy, with options including octreotide, somatostatin, or terlipressin 2, 6
Perform endoscopy within 12 hours once hemodynamically stable, with endoscopic variceal ligation (EVL) if varices are confirmed 2
Administer prophylactic antibiotics (maximum 7 days) to reduce mortality, infections, and rebleeding 2, 6

The American College of Cardiology recommends TIPS for refractory variceal bleeding when bleeding fails endoscopic and medical therapy 2, 6
Consider early/preemptive TIPS within 72 hours in high-risk patients: Child-Pugh C or MELD ≥19 2, 6

The American Heart Association recommends temporarily suspending NSBBs in acute bleeding with systolic BP <90 mmHg or MAP <65 mmHg, and using extreme caution or suspending in refractory ascites with hypotension 2
Absolute contraindications for NSBBs include severe bradycardia, heart block, severe asthma, and decompensated heart failure 2

The American Gastroenterological Association recommends against routinely correcting coagulation abnormalities before prophylactic band ligation in stable cirrhotic patients, as it provides no benefit 2
Do not use tranexamic acid in active variceal bleeding, as it is contraindicated 2

The American Association for the Study of Liver Diseases recommends considering liver transplantation in all patients with decompensated cirrhosis, as it is the most effective approach to reduce portal pressure and improve survival 2, 3